Increasing evidence suggests that the metabolic adaptations of T cells determine their function by reprogramming T-cell metabolism through checkpoints like IDO, IL4I1, and SIRT2, resulting in improved anti-cancer immune efficacy [163,164]. Here, SIRT2 is linked to cancer.